Edgewise Therapeutics Closes $50 Million Series B Financing – Financing to Support Advancing Company’s Lead Product Candidate for Muscular Dystrophy- Boulder, Colo., (September 17, 2019) – Edgewise Therapeutics, a preclinical company developing small molecule...
BrightInsight Raises Significant Capital to Enhance its Regulated Digital Health Platform and Accelerate Global Commercialization Today we announced the exciting news that BrightInsight raised significant capital from top healthcare venture capital firm, New Leaf...
Recent Comments